Showing 15 posts of 853 posts found.

NICE recommends Takeda’s Adcetris for previously untreated systemic anaplastic large cell lymphoma

July 9, 2020
Sales and Marketing Adcentris, NICE, Takeda, UK

NICE has announced it has recommended Takeda’s Adcetris (brentuximab vedotin), in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for use …


NICE to recommend Roche cancer treatment

June 26, 2020
Medical Communications NHS, NICE

NICE are set to recommend Roche’s Rozlytrek (Entrectinib) cancer treatment which will be the second histology drug to be recommended …

NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps

June 25, 2020
Sales and Marketing Mayzent, NHS, NICE, Novartis

Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …

NICE greenlights Roche’s Rozlytrek for ROS1+ advanced non-small cell lung cancer

June 15, 2020
Sales and Marketing NICE, Roche, Rozlytrek, UK, lung cancer

Roche’s Rozlytrek (entrectinib) has secured recommendation for NHS use in England and Wales after NICE backed the drug in final …

NICE reverses previous stance to recommend Roche’s Tecentriq in extensive-stage small-cell lung cancer

May 27, 2020
Research and Development, Sales and Marketing NICE, Roche, lung cancer, tecentriq

NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new …

NICE gives thumbs-up to Roche’s Kadcyla in HER2+ breast cancer sub-population

May 7, 2020
Sales and Marketing Cancer, Kadcyla, NHS, NICE, Roche, UK, breast cancer

NICE has revealed that it has recommended the NHS use of Roche’s Kadcyla (trastuzumab emtansine) for HER2+ breast cancer in …


NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer

April 21, 2020
Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …


NICE promotes Professor Gillian Leng as its new Chief Executive

March 18, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, UK, pharma

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng …


Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund

March 12, 2020
Sales and Marketing Cancer, Kidney cancer, MSD, NHS, NICE, blader cancer, keytruda, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for …


Teva’s Ajovy becomes first drug of its kind available on NHS for prevention of chronic migraine

March 12, 2020
Sales and Marketing NICE, Teva, ajovy, migraine, pharma

NICE has announced the authorisation of Teva’s anti-CGRP drug Ajovy (fremanezumab) for the prevention of chronic migraine in adult patients …


NICE shoots down Dupixent for severe asthma

March 9, 2020
Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …


NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease

March 4, 2020
Research and Development Avatrombopag, NHS, NICE, UK, chronic liver disease

UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England …


NICE recommends Celgene’s Revlimid combo for follicular lymphoma

February 27, 2020
Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma

NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …


NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

February 26, 2020
Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …

Latest content